We value speed, audacity, authenticity, grit, and empathy, and empower our teams to reimagine the status quo.
Location: United States, Tennessee, Nashville
Employees: 201-500
Total raised: $82M
Founded date: 1999
Investors 4
| Date | Name | Website |
| 10.07.2026 | Hildred | hildred.co... |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Shepherd V... | shepherdve... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.04.2013 | Series E | $33M | - |
| 10.06.2011 | - | $45M | - |
| 25.02.2007 | - | $4M | - |
Mentions in press and media 15
| Date | Title | Description |
| 12.11.2025 | Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine | Moxie—the all-in-one growth and operating engine trusted by 600+ of the nation's fastest-growing aesthetic practices—today announced two major initiatives shaping the future of aesthetic entrepreneurship and bridge the business gap in aesth... |
| 07.02.2025 | Crown Laboratories Completes Acquisition of Revance Therapeutics | NEW YORK--(BUSINESS WIRE)--Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revan... |
| 09.12.2024 | Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement | JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (... |
| 09.09.2024 | Sirsram Medical announces NMPA approval for DAXXIFY® | Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical ... |
| 12.08.2024 | Crown Laboratories and Revance Announce Entry Into Merger Agreement | Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the ... |
| 21.03.2022 | Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management | – $300 million note purchase agreement includes committed borrowings of $200 million and an additional option of uncommitted borrowings of up to $100 million – Cash runway extended into 2024 with $100 million in notes issued at closing and ... |
| 02.04.2013 | Revance Therapeutics Raises $33M in Series E Growth Financing | Revance Therapeutics, Inc., a Newark, California-based specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, raised $33m in Series E growth financing. Revance also co... |
| 02.04.2013 | Revance Therapeutics Grabs $33M Series E | NEWARK, CA, Privately held specialty biopharmaceutical company announced that it has raised $33 million of its Series E growth financing. >> Click here for more funding data on Revance Therapeutics >> To export Revance Thera... |
| 10.06.2011 | Revance Therapeutics Closes $45M Financing | Revance Therapeutics, Inc., a Newark, California-based biopharmaceutical company that has developed proprietary platform technology which enables local, targeted delivery of large macromolecules across skin, closed a $45m financing. The rou... |
| 04.01.2010 | Revance Raises $25M in Series D Financing | Revance Therapeutics, Inc., a Newark, CA-based biopharmaceutical company, announced the first $25m closing of a $35m Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII. The financing included returning invest... |
Show more